Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort

Rheumatology (United Kingdom)

Volumn 56, Issue 7, 2017, Pages 1111-1122

  Nevskaya, Tatiana ^a   Baron, Murray ^b   Pope, Janet E ^a   Hudson, Marie ^b   Gyger, Geneviève ^b   Larché, Maggie J ^c   Khalidi, Nader A ^d   Masetto, Ariel ^d   Sutton, Evelyn ^e   Robinson, David ^f   Rodriguez Reyna, Tatiana S ^g   Smith, Doug ^h   Thorne, Carter ⁱ   Fortin, Paul R ^j   Fritzler, Marvin J ^k  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

Activity; Assessment; European Scleroderma Research Group activity index; Predictive value; Severity; Systemic sclerosis

Indexed keywords

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSING CAPACITY OF CARBON MONOXIDE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; ERYTHROCYTE SEDIMENTATION RATE; EUROPEAN SCLERODERMA GROUP ACTIVITY INDEX; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; GENDER; GENERAL CONDITION DETERIORATION; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEALTH STATUS; HEART DISEASE; HUMAN; KIDNEY DISEASE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDSGER SEVERITY SCALE; MODIFIED RODNAN SKIN SCORE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SKIN DISEASE ASSESSMENT; SKINFOLD THICKNESS; SOUTH ASIAN; SYSTEMIC SCLEROSIS; AGED; CANADA; CROSS-SECTIONAL STUDY; DISABILITY; DISEASE COURSE; EUROPE; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SICKNESS IMPACT PROFILE; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; CANADA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SICKNESS IMPACT PROFILE;

EID: 85021741718     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex015     Document Type: Article

References (37)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4
2. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017-26
3. Bose N, Bena J, Chatterjee S. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther 2015;17:44
4. Prey S, Ezzedine K, Doussau A et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012;167:1138-44
5. van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology 2015;54:2126-33
6. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8
7. Valentini G, D'Angelo S, Della Rossa A et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5
8. Shao J, Tu D. The jackknife and the bootstrap. New York: Springer, 1995
9. Valentini G, Bencivelli W, Bombardieri S et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3
10. Fan X, Pope J, Baron M, Canadian Scleroderma Research Group. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2010;30:1205-10
11. Hanke K, Dahnrich C, Bruchner CS et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009;11:R28
12. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32:824-7
13. Le Roy EC, Black C, Fleischmajer et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5
14. Clements P, Lachenbruch P, Seibold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5
15. Pope J. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician-and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). Arthritis Care Res 2011;63(Suppl 11):S98-111
16. Fries JF, Spitz P, Kraines G, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
17. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91
18. Domsic RT, Rodriguez-Reyna T, Lucas M et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011;70:104-13
19. Medsger TA Jr, Bombardieri S, Czirjak L et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21(Suppl 29):S42-6
20. Sekhon S, Pope J, Baron M, Canadian Scleroderma Research Group. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. J Rheumatol 2010;37:591-8
21. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002;14:109-14
22. Khanna D, Furst DE, Hays RD et al. Minimally important difference in diffuse systemic sclerosis: results from the D-Penicillamine Study. Ann Rheum Dis 2006;65:1325-9
23. Knofczynski GT, Mundfrom D. Sample sizes when using multiple linear regression for prediction. Educ Psychol Measure 2008;68:431-42
24. Tabachnick BG, Fidell LS. Using multivariate statistics, 4th edn. Boston: Allyn and Bacon, 2001
25. Hugle T, Schuetz P, Daikeler T et al. Late-onset systemic sclerosis-a systematic survey of the EULAR scleroderma trials and research group database. Rheumatology 2011;50:161-5
26. Shand L, Lunt M, Nihtyanova S et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007;56:2422-31
27. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with dcSSc. Arthritis Rheum 2000;43:2437-44
28. Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol 2014;26:646-52
29. Ngian GS, Sahhar J, Wicks IP, Van Doornum S. Cardiovascular disease in systemic sclerosis-an emerging association? Arthritis Res Ther 2011;13:237
30. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women. The Reykjavik Study. Am J Epidemiol 2003;158:844-51
31. Jousilahti P Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease. A prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999;99:1165-72
32. Follansbee WP, Curtiss EI, Medsger TA et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with dcSSc. N Engl J Med 1984;310:142-8
33. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labelling claims. Washington, DC: U.S. Department of Health and Human Services, 2009
34. Hudson M, Impens A, Baron M et al. Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol 2010;37:2307-12
35. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42:426-9
36. Silver RM, Medsger TA Jr, Bolster MB. Systemic sclerosis and scleroderma variants: clinical aspects. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions: a textbook in rheumatology, 15th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:1633-1680
37. Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012;39:1971-8